Japanese deaths prompt Osteobond recall:
This article was originally published in Clinica
Executive Summary
Zimmer has recalled its bone adhesive Osteobond from Japan, following reports linking three deaths from sudden hypotension and cardiac arrest. The copolymer cement - a mixture of monomeric and polymeric methyl methacrylate with barium sulphate - was launched by the Bristol-Myers Squibb subsidiary in Japan in April, and has been used for joint replacements in 1800 patients since then. The company is claiming confidence in the product and says the recall is a safety measure.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.